The study is designed to develop novel assays for the differential diagnosis of human Chronic Myelogenous Leukemia (CML). The basic method involves the use molecular techniques to detect the Ph1 chromosomal translocation. Hybridization with a labeled DNA probe identifies novel junctions between the cellular abl proto-oncogene, from chromosome 9, and the phl gene from chromosome 22. In CML the junctions occur with small breakpoint cluster region (bcr), and can be detected readily in genomic DNA. Assays based on the detection of novel junctions in messenger RNA also will be developed. Clinical evaluation of the assays, in comparison with cytogenetic analysis, will be completed. The assays have commercial application as a clinical laboratory test for the diagnosis and monitoring of leukemia patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44CA039874-03
Application #
3506420
Study Section
Special Emphasis Panel (SSS (B1))
Project Start
1989-06-15
Project End
1991-05-31
Budget Start
1990-06-15
Budget End
1991-05-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Osi Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Uniondale
State
NY
Country
United States
Zip Code
11553